Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Solid Biosciences (SLDB) over the last 5 years, with Dec 2024 value amounting to -$3.06.

  • Solid Biosciences' EPS (Weighted Average and Diluted) fell 2.00% to -$1.02 in Q4 2024 from the same period last year, while for Dec 2024 it was -$3.06, marking a year-over-year increase of 36.78%. This contributed to the annual value of -$3.06 for FY2024, which is 36.65% up from last year.
  • Latest data reveals that Solid Biosciences reported EPS (Weighted Average and Diluted) of -$3.06 as of FY2024, which was up 36.65% from -$4.83 recorded in FY2023.
  • Solid Biosciences' EPS (Weighted Average and Diluted)'s 5-year high stood at -$3.06 during FY2024, with a 5-year trough of -$25.50 in FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$6.00, with a median of -$4.83 in 2023.
  • Data for Solid Biosciences' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 60.23% (in 2021) over the last 5 years.
  • Over the past 5 years, Solid Biosciences' EPS (Weighted Average and Diluted) (Yearly) stood at -$25.50 in 2020, then spiked by 60.23% to -$10.14 in 2021, then grew by 0.39% to -$10.10 in 2022, then spiked by 52.18% to -$4.83 in 2023, then surged by 36.65% to -$3.06 in 2024.